文献速递脑血管病

继发性卒中预防药物治疗的新视野

New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention.
PubMed 文献 · JAMA Neurol · 2020-01-01

本综述总结了II期和III期随机临床试验中显示对非心源性卒中预防有疗效信号的新兴治疗方法,并概述了在原发性卒中预防中有前景、可考虑进一步评估的药物方案。综述指出,尽管现有治疗和生活方式调整,缺血性卒中后仍有显著的卒中复发和心血管疾病残余风险。目前有多种新机制的抗血栓、降脂、抗炎和降糖药物正在随机临床试验中研究,有望减轻未来复发性卒中的负担。

要点

  • 低剂量利伐沙班联合阿司匹林用于临床动脉粥样硬化且有卒中史患者的二级预防值得进一步研究。
  • 两项国际随机临床试验正在评估口服因子XI抑制剂联合抗血小板药用于非心源性缺血性卒中二级预防。
  • GLP-1受体激动剂在减少卒中方面比其他心血管结局显示出持续更大的获益。

核心结论

  • 继发性卒中预防领域存在多个令人兴奋的新兴机会,随机临床试验正在研究具有新机制的新型抗血栓、降脂、抗炎和降糖药物,可能减少未来复发性卒中的负担。

研究设计与样本

  • 本综述总结了II期和III期随机临床试验中显示对非心源性卒中预防有疗效信号的新兴治疗方法,并概述了在原发性卒中预防中有前景的药物方案。

主要发现

  • 低剂量利伐沙班联合阿司匹林作为抗血栓选择,用于临床动脉粥样硬化且有卒中史患者的二级预防,值得进一步研究。
  • 两项国际随机临床试验正在评估口服因子XI抑制剂联合抗血小板药用于非心源性缺血性卒中二级预防的效用。
  • 他汀类药物强化降脂治疗已被证明可改善缺血性卒中复发和总体心血管风险。
  • PCSK9抑制剂被研究人员建议可提供额外的卒中复发保护,而靶向脂蛋白(a)的反义寡核苷酸疗法被报道作为未来降低脂蛋白(a)介导的残余心血管风险的治疗策略具有很大前景。
  • GLP-1受体激动剂是较新的降糖药物,近期受到关注,因为与其他心血管结局相比,其在减少卒中方面持续显示出更大的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Even with currently available therapies and lifestyle modifications following an ischemic stroke, there remains a substantial residual lifetime risk of stroke recurrence and cardiovascular morbidity. This review summarizes emerging novel therapeutic approaches that have demonstrated signals of efficacy for prevention of noncardioembolic stroke from phase II and phase III randomized clinical trials (RCTs) and provides an overview of drug regimens that have had promising results in primary stroke prevention and could be considered for further evaluation. OBSERVATIONS: After a minor acute ischemic stroke or transient ischemic attack, patients bear a high cardiovascular risk that is insufficiently addressed by long-term antiplatelet treatment. The potent combination of low-dose rivaroxaban with aspirin as an antithrombotic option for the secondary prevention in patients with clinical atherosclerosis and a history of previous stroke warrants further study. Two international RCTs are currently evaluating the utility of oral factor XI inhibitors combined with antiplatelets for secondary, noncardioembolic ischemic stroke prevention. Aggressive lipid management with statins has been shown to ameliorate ischemic stroke recurrence and total cardiovascular risk. Proprotein convertase subtilisin/kexin type 9 inhibitors are drug regimens that researchers have suggested confer additional protection against stroke recurrence, while antisense oligonucleotide therapies targeting lipoprotein(a) have been reported to hold great promise as a future therapeutic strategy to decrease the residual cardiovascular risk mediated through lipoprotein(a). Glucagon-like peptide-1 receptor agonists are newer antidiabetic medications, recently highlighted because of their consistently greater benefit on stroke reduction compared with other cardiovascular outcomes. CONCLUSIONS AND RELEVANCE: There are currently several exciting emerging opportunities in secondary stroke prevention, with RCTs investigating novel antithrombotic, hypolipidemic, anti-inflammatory, and antidiabetic agents with novel mechanisms that are likely to reduce the future burden of recurrent stroke.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Katsanos AH, Hart RG. New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. JAMA Neurol. 2020. PMID: 32716473. doi:10.1001/jamaneurol.2020.2494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。